PMMNG member Phil Falkowitz started taking Revlimid (lenalidomide) way back in 2001, during the Phase 1 clinical trial of Revlimid. That trial went well for him (and for Revlimid).
PMMNG members Nancy Stewart and Phil Falkowitz are shown in a couple of photos from the MMRF's Philadelphia 5K fundraiser on Saturday Nov. 11, 2017.
Many of us in the PMNNG consider Phil Falkowitz to be a larger-than-life inspiration. Now we can say that that is literally true.
A mural featuring a likeness of Phil is being featured at ASH 2017 by Celgene. This is a truly fitting honor for Phil because he was one of the first multiple myeloma patients to participate in a Revlimid (lenalidomide) trial. Phil also serves in Celgene's "Ambassadors" program, helping to educate other patients.
Congratulations, Phil, on this tribute. And thanks for all you do as an advocate!